EP
ANIK icon

Essential Partners’s Anika Therapeutics ANIK Stock Holding History

Essential Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.3K Sell
526
-41
-7% -$785 ﹤0.01% 1183
2026
Q2 		$8.29K Sell
567
-336
-37% -$4.98K ﹤0.01% 1309
2026
Q1 		$13.1K Buy
903
+246
+37% +$2.86K ﹤0.01% 1116
2025
Q4 		$6.31K Buy
657
+338
+106% +$3.24K ﹤0.01% 1336
2025
Q3 		$3K Buy
319
+314
+6,280% +$3K ﹤0.01% 1634
2025
Q2 		$53 Buy
+5
New +$63 ﹤0.01% 2145

Other funds holding ANIK

B
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's ANIK Position: Q3 2026 in Review

Essential Partners reduced its Anika Therapeutics (ANIK) stake by 7.2% in Q3 2026, selling an estimated $785 and leaving 526 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Essential Partners first reported a position in ANIK in Q2 2025 and has held it in 6 quarters since. The position peaked at $13.1K in Q1 2026. 9 funds tracked by Wall St. Rank hold ANIK as of Q3 2026.

  • Essential Partners held 526 shares of Anika Therapeutics worth $10.3K as of Q3 2026.
  • Essential Partners sold 41 Anika Therapeutics shares in Q3 2026, an estimated $785.
  • Anika Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1183 holding.
  • Essential Partners first reported a position in Anika Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Anika Therapeutics position peaked at $13.1K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.